Abstract: Uterine fibroids are the most common benign tumors in the female reproductive system, which can cause abnormal uterine bleeding, compression symptoms, abdominal pain and infertility. Currently the drug treatment effect is limited, it mainly relies on surgical treatment. GnRH-a inhibits the hypothalamic-pituitary-gonadal axis from a high position, reduces estrogen and progesterone in the blood of patients, reduces the volume of fibroids, and improves anemia and pelvic compression symptoms. Compared with oral drugs, it is easier to use, patient compliance is good, and the treatment effect is exact. The volume of the fibroids is reduced, which makes the laparoscopic surgery and the preservation of the uterus less difficult, and the postoperative recovery is fast. In patients with menopausal transition, with severe comorbidities and intolerance to surgery, the use of GnRH-a can also prevent surgery or suspend surgery, and control comorbidities. Pituitary gonadotropin secretion can be restored within 2 weeks, and normal menstrual cycle can be reconstructed after 6-8 weeks after stopping the usage of GnRH-a.

Key words: Uterine neoplasms, Leiomyoma, Gonadotropin-releasing hormone, Laparoscopes, Menopause